# EDGAR Filing Document

**Accession Number:** 0001760689
**File Stem:** 0001760689-23-000015
**Filing Date:** 2023-3
**Character Count:** 46279
**Document Hash:** b7aef1a83bfe172e52a088c9f411cf9d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001760689-23-000015.hdr.sgml**: 20230316

**ACCESSION NUMBER**: 0001760689-23-000015

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 29

**CONFORMED PERIOD OF REPORT**: 20230316

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230316

**DATE AS OF CHANGE**: 20230316

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Microvast Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001760689
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS ELECTRICAL MACHINERY, EQUIPMENT & SUPPLIES [3690]
- **IRS NUMBER:** 832530757
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38826
- **FILM NUMBER:** 23739671

**BUSINESS ADDRESS:**
- **STREET 1:** 12603 SOUTHWEST FREEWAY, SUITE 210
- **CITY:** STAFFORD
- **STATE:** TX
- **ZIP:** 77477
- **BUSINESS PHONE:** (281) 491-9595

**MAIL ADDRESS:**
- **STREET 1:** 12603 SOUTHWEST FREEWAY, SUITE 210
- **CITY:** STAFFORD
- **STATE:** TX
- **ZIP:** 77477

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tuscan Holdings Corp.
- **DATE OF NAME CHANGE:** 20181204

?xml version="1.0" ? mvst-20230316

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 16, 2023**

**Microvast Holdings, Inc.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38826** | **83-2530757** |
| **(State or other jurisdiction<br>of incorporation)** | **(Commission File Number)** | **(IRS. Employer<br>Identification No.)** |

---

**12603 Southwest Freeway, Suite 300 Stafford, Texas, 77477**

**(Address of principal executive offices, including zip code)**

**281-491-9505**

**(Registrant's telephone number, including area code)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common stock, par value $0.0001 per share** | **MVST** | **The NASDAQ Stock Market LLC** |
| **Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share** | **MVSTW** | **The NASDAQ Stock Market LLC** |

---

------

**Item 2.02 Results of Operations and Financial Condition.**

On March 16, 2023, Microvast Holdings, Inc. issued a press release announcing its consolidated financial results for the fourth quarter and year ended December 31, 2022. A copy of the press release and the slideshow is furnished herewith as Exhibit 99.1 and 99.2, respectively to this Current Report on Form 8-K and each is incorporated herein by reference.

The information furnished in this Current Report on Form 8-K and the accompanying Exhibit 99.1 and 99.2 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by reference in such a filing.

**Item 9.01 Financial Statements and Exhibits**

**(d)*Exhibits***

---

| | |
|:---|:---|
| **Exhibit No.**  | **Description**  |
| 99.1 | <u>[Press Release dated March 16, 2023](mvst2022q4ex991earningspre.htm)</u> |
| 99.2 | <u>[Presentation dated March 16, 2023](q42022earningsslides-16m.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| Date: March 16, 2023 | **MICROVAST HOLDINGS, INC.** | **MICROVAST HOLDINGS, INC.** |
|  | By: | /s/ Craig Webster |
|  | Name: | Craig Webster |
|  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**Microvast Reports 2022 Financial Results**

35% year over year increase in revenue

121% year over year increase in gross profit

>3.5x year over year increase in backlog to $410.5 million

STAFFORD, TX., March 16, 2023 – Microvast Holdings, Inc. (NASDAQ:MVST) ("Microvast" or the "Company"), a technology innovator that designs, develops and manufactures lithium-ion battery solutions, announced today its consolidated financial results for the fourth quarter and full fiscal year ended December 31, 2022 ("Q4 2022" and "FY 2022," respectively).

"I am proud of our accomplishments in 2022," said Yang Wu, Microvast's Founder, Chairman, President and Chief Executive Officer. "We reached a number of key milestones, including the launch of our new lithium-ion battery cells and next generation battery pack products, the launch of the Microvast Energy division, followed by an award of a 1.2GWh utility scale ESS contract and a $200 million grant from the U.S. Department of Energy for the construction of a new separator manufacturing facility. We are excited for the year ahead as we bring our new battery technologies to serial production and already have significant demand across our commercial vehicle and energy storage systems customers."

"We are pleased to report another quarter of stable growth, and we closed 2022 with a record backlog of $410.5 million, which puts us in a great position to execute our high growth plans for the years ahead," said Craig Webster, Mircovast's Chief Financial Officer. "As we bring additional capacity online this year, we will add approximately $1 billion of new revenue potential annually for our new 53.5Ah cell, which already accounts for over 80% of our backlog. We believe that the strong demand we are seeing along with the anticipated benefits of IRA puts us on a path to achieve profitability within the next two to three years."

**Full Year 2022 Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenue of $204.5 million, compared to $152.0 million in 2021, an increase of 35%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross profit increased by 121% to $9.1 million from gross loss of $42.7 million in 2021; Non-GAAP adjusted gross profit of $16.8 million, compared to non-GAAP adjusted gross loss of $38.5 million in 2021; Non-GAAP adjusted gross margin increased to 8.2%, up from negative 25.3% in 2021

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating expenses of $170.7 million, compared to $157.4 million in 2021; Adjusted operating expenses of $96.5 million, compared to $97.6 million in 2021

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss of $158.2 million, compared to net loss of $206.5 million in 2021; Non-GAAP adjusted net loss of $77.3 million, compared to non-GAAP adjusted net loss of $135.0 million in 2021

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of negative $56.7 million, compared to Adjusted EBITDA of negative $109.3 million in 2021

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Backlog as of December 31, 2022 was $410.5 million, representing growth of 258.5% compared to $114.5 million in backlog as of December 31, 2021 and sequential growth of 192.0% compared to $140.6 million in backlog at September 30, 2022.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Capital expenditures of $150.9 million, compared to $87.9 million in 2021, driven by investments in manufacturing capacity expansions in Huzhou, China and Clarksville, Tennessee

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash, cash equivalents, restricted cash and short-term investment of $327.7 million as of December 31, 2022

------

**Fourth Quarter 2022 Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenue of $64.8 million, compared to $66.8 million in the fourth quarter of 2021, a decrease of 3.0%

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Gross profit increased to $2.2 million from $1.2 million in 2021; Non-GAAP adjusted gross profit of $4.2 million, compared to non-GAAP adjusted gross profit of $3.1 million in Q4 2021; Non-GAAP adjusted gross margin increased to 6.4% from 4.7% in Q4 2021

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating expenses of $37.3 million, compared to $52.2 million in Q4 2021; Adjusted operating expenses of $21.4 million compared to $39.6 million in Q4 2021

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Net loss was $33.7 million, compared to $46.6 million in Q4 2021; Non-GAAP adjusted net loss of $15.9 million, compared to non-GAAP adjusted net loss of $33.4 million in Q4 2021

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted EBITDA of negative $11.8 million, compared to Adjusted EBITDA of negative $27.3 million in Q4 2021

**2023 Outlook**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Full year 2023 revenue in the range of $336 million and $358 million, reflecting year over year growth of 65% - 75% underpinned by record backlog of $410.5 million

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Deliveries of new 53.5Ah cell starting in second quarter from new cell and module line in Huzhou, China and in fourth quarter from Tennessee, US

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Revenue for the first quarter ending March 31, 2023 between $38 million and $40 million, representing growth of approximately 3.5% - 9% compared to $36.7 million for the first quarter ended March 31, 2022

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Capital expenditures for the full year in the range of $180 to $210 million.

**Webcast Information**

Microvast management will host a conference call and webcast on March 16, 2023, at 4:00 p.m. Central Time, to discuss the Company's financial results. The live webcast and accompanying slide presentation will be accessible from the Events & Presentations section of Microvast's investor relations website (https://ir.microvast.com/events-presentations/events). A replay will be available following the conclusion of the event. Investment community professionals interested in participating in the Q&A session may join the call by dialing +1 (631) 891-4304.

**About Microvast**

Founded in Houston, Texas in 2006 as a research and technology driven company, Microvast has evolved into a global leader in the design, development and manufacture of battery solutions for mobile and stationary applications. Microvast provides a broad portfolio of fast-charging lithium-ion battery solutions, with different chemistries, performance characteristics and price points to meet the diverse requirements of its customer base. Microvast is renowned for its cutting-edge cell technology and its vertical integration capabilities which extend from core battery chemistry (cathode, anode, electrolyte, and separator) to modules and packs.

Since placing its first battery systems into operation in electric buses more than a decade ago, Microvast has expanded its business to serve a broad range of commercial, passenger and specialty vehicles, including mining, material handling, and power vehicles and equipment, as well as grid-scale energy storage applications.

For more information, please visit www.microvast.com or follow us on LinkedIn or Twitter (@microvast).

Microvast is a technology innovator that designs, develops and manufactures lithium-ion battery solutions. Microvast is renowned for its cutting-edge cell technology and its vertical integration capabilities which extend from core battery chemistry (cathode, anode, electrolyte, and separator) to modules and packs. By integrating the process from raw material

------

to system assembly, Microvast has developed a family of products covering a breadth of market applications, including electric vehicles, energy storage and battery components. Microvast was founded in 2006 and is headquartered near Houston, Texas. For more information, please visit www.microvast.com or follow us on LinkedIn or Twitter (@microvast).

**Contact:**

Investor Relations

ir@microvast.com

(346) 309-2562

Monica Gould

monica@blueshirtgroup.com

(212) 871-3927

**Non-GAAP Financial Measures**

To provide investors with additional information regarding our financial results, Microvast has disclosed in this earnings release non-GAAP financial measures, including non-GAAP adjusted gross profit (loss), non-GAAP adjusted EBITDA and non-GAAP adjusted net loss, which are non-GAAP financial measures as defined under the rules of the SEC. These are intended as supplemental measures of our financial performance that are not required by, or presented in accordance with U.S. generally accepted accounting principles ("GAAP").

Reconciliations to the most comparable GAAP measures, gross profit (loss) and net income (loss), are contained in tabular form in the unaudited financial statements below. Non-GAAP adjusted gross profit (loss) is GAAP gross profit as adjusted for non-cash stock-based compensation expense included in cost of revenues. Non-GAAP adjusted net loss is GAAP net loss as adjusted for non-cash stock-based compensation expense and change in valuation of warrant liabilities and convertible notes. Non-GAAP adjusted EBITDA is defined as net loss excluding depreciation and amortization, non-cash settled share-based compensation expense, interest expense, interest income, changes in fair value of our warrant liability and convertible notes and income tax expense or benefit.

We use non-GAAP adjusted gross profit (loss), non-GAAP adjusted EBITDA and non-GAAP adjusted net loss for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We consider them to be important measures because they help illustrate underlying trends in our business and our historical operating performance on a more consistent basis. We believe that these non-GAAP financial measures, when taken together with their most directly comparable GAAP measures, gross profit (loss) and net income (loss), provide meaningful supplemental information regarding our performance by excluding certain items that may not be indicative of our recurring core business operating results.

We believe that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. These non-GAAP financial measures also facilitate management's internal comparisons to our historical performance. We believe these non-GAAP financial measures are useful to investors both because (1) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (2) they are used by our institutional investors and the analyst community to help them analyze the health of our business. Accordingly, we believe that these non-GAAP financial measures provide useful information to investors and others in understanding and evaluating our operating results in the same manner as our management team and board of directors.

Non-GAAP financial measures have limitations as an analytical tool, and you should not consider them in isolation, or as a substitute for, financial information prepared in accordance with GAAP. For example, our calculation of non-GAAP adjusted EBITDA may differ from similarly titled non-GAAP measures, if any, reported by our peer companies, or our peer companies may use other measures to calculate their financial performance, and therefore our use of non-GAAP adjusted EBITDA may not be directly comparable to similarly titled measures of other companies. The principal limitation of non-GAAP adjusted EBITDA is that it excludes significant expenses and income that are required by GAAP to be recorded in our financial statements. In addition, it is subject to inherent limitations as it reflects the exercise of judgments by management about which expense and income are excluded or included in determining this non-GAAP financial measure. In order to compensate for these limitations, management presents non-GAAP financial measures in connection with GAAP results. In addition, such financial information is unaudited and does not conform to SEC Regulation S-X and,

------

as a result, such information may be presented differently in our future filings with the SEC. For example, with respect to the warrant liability resulting from the merger, we now exclude changes in fair value from net loss in our non-GAAP adjusted EBITDA and non-GAAP adjusted net loss calculation, which had not been done in prior periods.

**Cautionary Statement Regarding Forward-Looking Statements**

This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "objective," "plan," "project," "predict," "outlook" "should," "will," "would," or the negative of these terms, or other comparable terminology intended to identify statements about the future. These forward-looking statements include, but are not limited to, statements regarding our industry and market sizes, and future opportunities for us. Such forward-looking statements are based upon the current beliefs and expectations of management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements.

Many factors could cause actual results and the timing of events to differ materially from the anticipated results or other expectations expressed in the forward-looking statements, including, among others: (1) changes in the highly competitive market in which we compete, including with respect to our competitive landscape, technology evolution or regulatory changes; (2) risk that we may not be able to execute our growth strategies or achieve profitability; (3) risks of operations in China; (4) the impact of inflation; (5) changes in availability and price of raw materials; (6) changes in the markets that we target; (7) heightened awareness of environmental issues and concern about global warming and climate change; (8) risk that we are unable to secure or protect our intellectual property; (9) risk that our customers or third-party suppliers are unable to meet their obligations fully or in a timely manner; (10) risk that our customers will adjust, cancel or suspend their orders for our products; (11) risk that we will need to raise additional capital to execute our business plan, which may not be available on acceptable terms or at all; (12) risk of product liability or regulatory lawsuits or proceedings relating to our products or services; (13) economic, financial and other impacts of the coronavirus ("COVID-19") pandemic, including global supply chain disruptions; and (14) the conflict between Russia and Ukraine and any restrictive actions that have been or may be taken by the U.S. and/or other countries in response thereto, such as sanctions or export controls. Microvast's annual, quarterly and other filings with the U.S. Securities and Exchange Commission identify, address and discuss these and other factors in the sections entitled "Risk Factors."

Actual results, performance or achievements may differ materially, and potentially adversely, from any forward-looking statements and the assumptions on which those forward-looking statements are based. There can be no assurance that the data contained herein is reflective of future performance to any degree. You are cautioned not to place undue reliance on forward-looking statements as a predictor of future performance as forward-looking statements are based on estimates and assumptions that are inherently subject to various significant risks, uncertainties and other factors, many of which are beyond our control. All information set forth herein speaks only as of the date hereof, and we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date hereof except as may be required under applicable securities laws. Forecasts and estimates regarding our industry and end markets are based on sources we believe to be reliable, however, there can be no assurance these forecasts and estimates will prove accurate in whole or in part.

------

**MICROVAST HOLDINGS, INC.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

**(In thousands of U.S. dollars, except share and per share data, or as otherwise noted)**

---

| | | |
|:---|:---|:---|
| | **December 31, 2021** | **December 31, 2022** |
| **Assets** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $480931 | $231420 |
| &nbsp;&nbsp;&nbsp;Restricted cash, current | 55178 | 70732 |
| &nbsp;&nbsp;&nbsp;Short-term investments |  | 25070 |
| &nbsp;&nbsp;&nbsp;Accounts receivable (net of allowance for doubtful accounts of $5,005 and $4,407 as of December 31, 2021 and 2022, respectively) | 88717 | 119304 |
| &nbsp;&nbsp;&nbsp;Notes receivable | 11144 | 2196 |
| &nbsp;&nbsp;&nbsp;Inventories, net | 53424 | 84252 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 17127 | 12093 |
| &nbsp;&nbsp;&nbsp;Amounts due from related parties | 85 |  |
| **Total Current Assets** | **706606** | **545067** |
| Restricted cash, non-current |  | 465 |
| Property, plant and equipment, net | 253057 | 335140 |
| Land use rights, net | 14008 | 12639 |
| Acquired intangible assets, net | 1882 | 1636 |
| Operating lease right-of-use assets |  | 16368 |
| Other non-current assets | 19738 | 73642 |
| **Total Assets** | $**995291** | $**984957** |
| **Liabilities** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $40408 | $44985 |
| &nbsp;&nbsp;&nbsp;Advance from customers | 1526 | 54207 |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 58740 | 66720 |
| &nbsp;&nbsp;&nbsp;Income tax payables | 666 | 658 |
| &nbsp;&nbsp;&nbsp;Short-term bank borrowings | 13301 | 17398 |
| &nbsp;&nbsp;&nbsp;Notes payable | 60953 | 68441 |
| **Total Current Liabilities** | **175594** | **252409** |
| Long-term bank borrowings |  | 28997 |
| Long-term bonds payable | 73147 | 43888 |
| Warrant liability | 1105 | 126 |
| Share-based compensation liability | 18925 | 131 |
| Operating lease liabilities |  | 14347 |
| Other non-current liabilities | 39822 | 32082 |
| **Total Liabilities** | $**308593** | $**371980** |
| Total Shareholders' Equity | **686698** | **612977** |
| **Total Liabilities and Shareholders' Equity** | $**995291** | $**984957** |

---

------

**MICROVAST HOLDINGS, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(In thousands of U.S. dollars, except share and per share data, or as otherwise noted)**

---

| | | |
|:---|:---|:---|
| | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
| | **2021** | **2022** |
| Revenues | $151976 | $204495 |
| Cost of revenues | (194719) | (195422) |
| **Gross (loss)/profit** | **(42743)** | **9073** |
| **Operating expenses:** |  |  |
| General and administrative expenses | (101632) | (104572) |
| Research and development expenses | (34385) | (43508) |
| Selling and marketing expenses | (21431) | (22611) |
| **Total operating expenses** | **(157448)** | **(170691)** |
| Subsidy income | 6127 | 1672 |
| **Loss from operations** | **(194064)** | **(159946)** |
| **Other income and expenses:** |  |  |
| Interest income | 446 | 3179 |
| Interest expense | (5411) | (3323) |
| Loss on changes in fair value of Bridge Notes | (9861) |  |
| Gain on changes in fair value of warrant liability | 2469 | 979 |
| Other (expense) income, net | (62) | 944 |
| **Loss before provision for income tax** | **(206483)** | **(158167)** |
| Income tax expense |  | (33) |
| **Net loss** | $**(206483)** | $**(158200)** |
| Less: Accretion of Series C1 Preferred | 2257 |  |
| Less: Accretion of Series C2 Preferred | 5132 |  |
| Less: Accretion of Series D1 Preferred | 10708 |  |
| Less: Accretion for noncontrolling interests | 9523 |  |
| **Net loss attributable to common stock shareholders of Microvast Holdings, Inc.** | $**(234103)** | $**(158200)** |
| **Net loss per share attributable to Common Stock shareholders of Microvast Holdings, Inc.** |  |  |
| Basic and diluted | $(1.26) | $(0.52) |
| Weighted average shares used in calculating net loss per share of common stock: |  |  |
| Basic and diluted | 185896482 | 303279188 |

---

------

**MICROVAST HOLDINGS, INC.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Unaudited, in thousands of U.S. dollars, except share and per share data, or as otherwise noted)**

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** |
| | **2021** | **2022** |
| Revenues | $66772 | $64797 |
| Cost of revenues | (65619) | (62571) |
| **Gross profit** | **1153** | **2226** |
| **Operating expenses:** |  |  |
| General and administrative expenses | (33822) | (21551) |
| Research and development expenses | (11186) | (10498) |
| Selling and marketing expenses | (7189) | (5242) |
| **Total operating expenses** | **(52197)** | **(37291)** |
| Subsidy income | 3451 | 439 |
| **Loss from operations** | **(47593)** | **(34626)** |
| **Other income and expenses:** |  |  |
| Interest income | 142 | 1575 |
| Interest expense | (781) | (858) |
| Other (expense) income, net | (87) | 186 |
| Gain on changes in fair value of warrant liability | 1356 | 58 |
| **Loss before provision for income tax** | **(46963)** | **(33665)** |
| Income tax benefit (expense) | 324 | (33) |
| **Net loss** | $**(46639)** | $**(33698)** |

---

------

**MICROVAST HOLDINGS, INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(In thousands of U.S. dollars, except share and per share data, or as otherwise noted)**

---

| | | |
|:---|:---|:---|
| | **Year Ended**<br>**December 31,** | **Year Ended**<br>**December 31,** |
| | **2021** | **2022** |
| Cash flows from operating activities |  |  |
| &nbsp;&nbsp;&nbsp;Net loss | $(206483) | $(158200) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash generated from/(used in) operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Loss /(Gain) on disposal of property, plant and equipment | 13 | (14) |
| &nbsp;&nbsp;&nbsp;Depreciation of property, plant and equipment | 19975 | 19811 |
| &nbsp;&nbsp;&nbsp;Amortization of land use rights and intangible assets | 738 | 554 |
| &nbsp;&nbsp;&nbsp;Noncash lease expenses |  | 2214 |
| &nbsp;&nbsp;&nbsp;Share-based compensation | 82894 | 90808 |
| &nbsp;&nbsp;&nbsp;Changes in fair value of warrant liability | (2469) | (979) |
| &nbsp;&nbsp;&nbsp;Changes in fair value of Bridge Notes | 9861 |  |
| &nbsp;&nbsp;&nbsp;Allowance of doubtful accounts | 721 | 1640 |
| &nbsp;&nbsp;&nbsp;Provision for obsolete inventories | 18295 | 4789 |
| &nbsp;&nbsp;&nbsp;Impairment loss from property, plant and equipment | 2443 | 1798 |
| &nbsp;&nbsp;&nbsp;Product warranty | 52932 | 14097 |
| Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Notes receivable | 10016 | 3187 |
| &nbsp;&nbsp;&nbsp;Accounts receivable | (11844) | (38924) |
| &nbsp;&nbsp;&nbsp;Inventories | (25892) | (43694) |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | (10980) | 3628 |
| &nbsp;&nbsp;&nbsp;Amounts due from/to related parties | (84) | 85 |
| &nbsp;&nbsp;&nbsp;Operating lease right-of-use assets |  | (19375) |
| &nbsp;&nbsp;&nbsp;Other non-current assets | (2135) | (282) |
| &nbsp;&nbsp;&nbsp;Notes payable | 24159 | 13490 |
| &nbsp;&nbsp;&nbsp;Accounts payable | (2499) | 7146 |
| &nbsp;&nbsp;&nbsp;Advance from customers | (971) | 53022 |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other liabilities | (5947) | (24674) |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities |  | 14999 |
| &nbsp;&nbsp;&nbsp;Other non-current liabilities | 2218 | 946 |
| &nbsp;&nbsp;&nbsp;Income tax payables |  |  |
| **Net cash used in operating activities** | **(45039)** | **(53928)** |
| Cash flows from investing activities |  |  |
| &nbsp;&nbsp;&nbsp;Purchases of property, plant and equipment | (87862) | (150880) |
| &nbsp;&nbsp;&nbsp;Proceeds on disposal of property, plant and equipment |  | 5 |
| &nbsp;&nbsp;&nbsp;Purchase of short-term investments |  | (25070) |
| **Net cash used in investing activities** | **(87862)** | **(175945)** |
| Cash flows from financing activities |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from bank borrowings | 38926 | 58708 |
| &nbsp;&nbsp;&nbsp;Repayment of bonds payable |  | (29259) |
| &nbsp;&nbsp;&nbsp;Repayment of bank borrowings | (37568) | (24482) |
| &nbsp;&nbsp;&nbsp;Loans borrowing from related parties | 8426 |  |
| &nbsp;&nbsp;&nbsp;Repayment of related party loans | (8426) |  |
| &nbsp;&nbsp;&nbsp;Cash received from the trust account upon Merger, net of transaction costs | 222629 |  |
| &nbsp;&nbsp;&nbsp;Cash received from Private Investment in Public Equity ("PIPE") investors upon Merger | 482500 |  |
| &nbsp;&nbsp;&nbsp;Payment to exited noncontrolling interests | (139038) |  |
| &nbsp;&nbsp;&nbsp;Issuance of Bridge Notes | 57500 |  |
| **Net cash generated from financing activities** | **624949** | **4967** |
| Effect of exchange rate changes | 2865 | (8586) |
| Increase (Decrease) in cash, cash equivalents and restricted cash | 494913 | (233492) |
| Cash, cash equivalents and restricted cash at beginning of the year | 41196 | 536109 |
| Cash, cash equivalents and restricted cash at end of the year | $**536109** | $**302617** |

---

------

**MICROVAST HOLDINGS, INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS - continued**

**(In thousands of U.S. dollars, except share and per share data, or as otherwise noted)**

---

| | | |
|:---|:---|:---|
| | **Year Ended<br>December 31,** | **Year Ended<br>December 31,** |
| | **2021** | **2022** |
| Reconciliation to amounts on consolidated balance sheets |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $480931 | $231420 |
| &nbsp;&nbsp;&nbsp;Restricted cash | 55178 | 71197 |
| &nbsp;&nbsp;&nbsp;**Total cash, cash equivalents and restricted cash** | $**536109** | $**302617** |

---

------

**MICROVAST HOLDINGS, INC.**

**RECONCILIATION OF GROSS PROFIT (LOSS) TO ADJUSTED GROSS PROFIT (LOSS)**

**(In thousands of U.S. dollars, except share and per share data, or as otherwise noted)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Twelve Months Ended<br>December 31,** | **Twelve Months Ended<br>December 31,** |
| | **2021** | **2022** | **2021** | **2022** |
| Revenues | $66772 | $64797 | $151976 | $204495 |
| Cost of revenues | (65619) | (62571) | (194719) | (195422) |
| **Gross profit/(loss) (GAAP)** | $**1153** | $**2226** | $**(42743)** | $**9073** |
| Gross margin | 1.7% | 3.4% | (28.1)% | 4.4% |
| Non-cash settled share-based compensation (included in cost of revenues) | 1978 | 1932 | 4262 | 7677 |
| **Adjusted gross profit/(loss) (non-GAAP)** | $**3131** | $**4158** | $**(38481)** | $**16750** |
| Adjusted gross margin (non-GAAP) | 4.7% | 6.4% | (25.3)% | 8.2% |

---

------

**MICROVAST HOLDINGS, INC.**

**RECONCILIATION OF NET LOSS TO ADJUSTED NET LOSS**

**(In thousands of U.S. dollars, except share and per share data, or as otherwise noted)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Twelve Months Ended<br>December 31,** | **Twelve Months Ended<br>December 31,** |
| | **2021** | **2022** | **2021** | **2022** |
| **Net loss (GAAP)** | $**(46639)** | $**(33698)** | $**(206483)** | $**(158200)** |
| Loss on changes in fair value of convertible notes |  |  | 9861 |  |
| Gain on changes in fair value of warrant liability | (1356) | (58) | (2469) | (979) |
| Non-cash settled share-based compensation | 14581 | 17867 | 64086 | 81906 |
| **Adjusted Net Loss (non-GAAP)** | $**(33414)** | $**(15889)** | $**(135005)** | $**(77273)** |

---

------

**MICROVAST HOLDINGS, INC.**

**RECONCILIATION OF NET LOSS TO EBITDA AND ADJUSTED EBITDA**

**(In thousands of U.S. dollars, except share and per share data, or as otherwise noted)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended<br>December 31,** | **Three Months Ended<br>December 31,** | **Twelve Months Ended<br>December 31,** | **Twelve Months Ended<br>December 31,** |
| | **2021** | **2022** | **2021** | **2022** |
| **Net loss (GAAP)** | $**(46639)** | $**(33698)** | $**(206483)** | $**(158200)** |
| Interest expense, net | 639 | (717) | 4965 | 144 |
| Income tax expense | (324) | 33 |  | 33 |
| Depreciation and amortization | 5816 | 4784 | 20713 | 20365 |
| **EBITDA (non-GAAP)** | $**(40508)** | $**(29598)** | $**(180805)** | $**(137658)** |
| Loss on changes in fair value of convertible notes |  |  | 9861 |  |
| Gain on changes in fair value of warrant liability | (1356) | (58) | (2469) | (979) |
| Non-cash settled share-based compensation | 14581 | 17867 | 64086 | 81906 |
| **Adjusted EBITDA (non-GAAP)** | $**(27283)** | $**(11789)** | $**(109327)** | $**(56731)** |

---

## Exhibit 99.2

![](q42022earningsslides-16m001.jpg)

q4 2022 \| Fy 2022

------

![](q42022earningsslides-16m002.jpg)

Forward-Looking Statements This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "believe," "intend," "plan," "projection," "guidance," "outlook" or words of similar meaning. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results, performance or achievements may differ materially, and potentially adversely, from any projections and forward-looking statements and the assumptions on which those forward-looking statements are based. All information set forth herein speaks only as of the date hereof and we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication. Forecasts and estimates regarding Microvast's industry and end markets are based on sources we believe to be reliable, however there can be no assurance these forecasts and estimates will prove accurate in whole or in part. Microvast's annual, quarterly and other filings with the U.S. Securities and Exchange Commission identify, address and discuss these and other factors in the sections entitled "Risk Factors." Non-GAAP Financial Measures This presentation contains adjusted gross profit, adjusted operating loss and adjusted net loss, which are non-GAAP financial measures. Adjusted gross profit is GAAP gross profit as adjusted for non-cash stock-based compensation expense included in cost of revenues. Adjusted operating loss is GAAP operating loss as adjusted for non-cash stock-based compensation expense included in cost of revenues and operating expense . Adjusted net loss is GAAP net loss as adjusted for non-cash stock-based compensation expense and change in on valuation of warrant liabilities and convertible notes. In addition to Microvast's results determined in accordance with GAAP, Microvast's management uses these non-GAAP financial metrics to evaluate the company's ongoing operations and for internal planning and forecasting purposes. We believe that this non-GAAP financial information, when taken collectively, may be helpful to investors in assessing Microvast's operating performance. We believe that the use of these non-GAAP metrics provides an additional tool for investors to use in evaluating ongoing operating results and trends because it eliminates the effect of financing, non-recurring items, capital expenditures, and non-cash expenses. In addition, our presentation of adjusted gross profit, adjusted operating loss and adjusted net loss should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items. Our computation of non-GAAP financial metrics may not be comparable to other similarly titled measures computed by other companies because not all companies calculate these measures in the same fashion. Because of these limitations, these non-GAAP financial metrics should not be considered in isolation or as a substitute for performance measures calculated in accordance with GAAP. We compensate for these limitations by relying primarily on our GAAP results and using non-GAAP financial metrics on a supplemental basis. Investors should review the reconciliations in this presentation and not rely on any single financial measure to evaluate our business. Disclaimer

------

![](q42022earningsslides-16m003.jpg)

3 2022 Overview Q4 2022 \| fy 2022 35% revenue growth year over year to $204.5M >3.5x increase in backlog position $410.5M driven by energy storage business in the U.S. and strong demand in Europe = Established Microvast Energy division in Colorado substantially expanding our addressable market to energy storage and secured 1.2GWh utility-scale project in the U.S. grant for our unique polyaramid separator technology. Collaborating with GM to develop a specialized separator Selected by U.S. Dept. of Energy for $200M Expanded partnership with Iveco for multiple additional platforms in Europe fully automated line in Huzhou for HpCO-53.5Ah cell production and began initial shipments 2GWh Our new US cell and module facility in Clarksville, TN in full construction mode, equipment ordered and direct beneficiary of IRA credits 2GWh Our new first win for

------

![](q42022earningsslides-16m004.jpg)

Q4 highlights

------

![](q42022earningsslides-16m005.jpg)

5 Steady Business Growth Through Production Ramp-Up Period Q4 2022 § Raw material prices, especially lithium § Worldwide inflationary pressures § Increasing rate environment, led by Fed tightening § Staff impact due to China removing Covid Zero Policy $364.7M $410.5M$64.8M Revenue (-3.0% YoY) 4GWh 53.5Ah capacity expansions Order Intake Sales Backlog Q4 KEY STATSCHALLENGES Microvast Energy division secures 1.2GWh ESS project, one of the largest of its kind in the U.S. Manufacturing capacity expansion projects near completion in Huzhou and well underway in Clarksville, TN Increasing orders for our next generation battery products (HpCO-53.5Ah cells) by commercial vehicle customers Kalmar Partnership extended through 2026 HIGHLIGHTS Received major orders for Gen 4 battery packs from airport cargo handling OEM Trepel Mafi

------

![](q42022earningsslides-16m006.jpg)

6 Major Product Developments in the Global Commercial Vehicle Market Q4 2022 OEM & Market Vehicle Battery Type Highlights 98 – 128 kWh HpCO-53.5Ah Full electric skateboard platform Full electric agricultural tractor HpCO-53.5Ah MV-C Gen 4 pack Full day operation, one hour of recharge to 100% power Broad spectrum of vehicle types Delivery plan in next 3 years: 175 MWh HpCO-53.5Ah Further opportunities in US and EMEA markets Growth in demand for hybrid HD truck Hybrid HD Trucks MpCO-21/48Ah, MV-B/C Gen 3/4 Innovative CV startup Europe ChinaEuropeEurope

------

![](q42022earningsslides-16m007.jpg)

7 Q4 2022 Highlights Q4 2022 Q4 ORDER INTAKE O N G O IN G M A JO R O R D E R ~$10M Airport cargo handling E-bus ~$6M Stable business growth with existing customers & new projects with $364.7M Q4 order value.

------

![](q42022earningsslides-16m008.jpg)

FINANCIALS

------

![](q42022earningsslides-16m009.jpg)

9 Condensed Consolidated Statement of Operations (USD'000) Q4 2022 \| FY 2022 GAAP Income Statement Three-Month Ended December 31 Twelve-Month Ended December 31 2021 2022 YoY(%) 2021 2022 YoY (%) Revenue 66,772 64,797 -3% 151,976 204,495 35% Cost of revenues (65,619) (62,571) -5% (194,719) (195,422) - Gross Profit 1,153 2,226 93% (42,743) 9,073 121% Gross Margin 1.7% 3.4% 99% -28.1% 4.4% 116% Selling and marketing expenses (7,189) (5,242) -27% (21,431) (22,611) 6% General and administrative (33,822) (21,551) -36% (101,632) (104,572) 3% Research and development expenses (11,186) (10,498) -6% (34,385) (43,508) 27% Operating expense (52,197) (37,291) -29% (157,448) (170,691) 8% Subsidy Income 3,451 439 -87% 6,127 1,672 -73% Operating loss (47,593) (34,626) -27% (194,064) (159,946) -18% Loss on changes in fair value of convertible notes - - - (9,861) - -100% Change in fair value of warrant liability 1,356 58 -96% 2,469 979 -60% Others (726) 903 -224% (5,027) 800 -116% Loss before income tax (46,963) (33,665) -28% (206,483) (158,167) -23% Income tax 324 (33) -110% - (33) 100% Net loss (46,639) (33,698) -28% (206,483) (158,200) -23%

------

![](q42022earningsslides-16m010.jpg)

10 2022 Adjusted Financials Non-GAAP (USD'000) Q4 2022 \| FY 2022 Cost of Sales Adjustments Three-Month Ended December 31 Twelve-Month Ended December 31 Three-Month Ended December 31 Twelve-Month Ended December 31 2021 2022 2021 2022 2021 2022 2021 2022 Revenue 66,772 64,797 151,976 204,495 Non-Cash Settled SBC 1,978 1,932 4,262 7,677 Adjusted Cost of sales (non-GAAP) (63,641) (60,639) (190,457) (187,745) Adjusted gross (loss) / profit (non- GAAP) 3,131 4,158 (38,481) 16,750 Adjusted gross margin (non-GAAP) 4.7% 6.4% -25.3% 8.2% Operating Expense Adjustments Three-Month Ended December 31 Twelve-Month Ended December 31 Adjusted Operating Expense (39,594) (21,356) (97,624) (96,462) 2021 2022 2021 2022 Adjusted Operating Loss (non-GAAP) (33,012) (16,759) (129,978) (78,040) Non-Cash Settled SBC 12,603 15,935 59,824 74,229 Adjusted Net Loss (non-GAAP) (33,414) (15,889) (135,005) (77,273) Net Loss Adjustments Three-Month Ended December 31 Twelve-Month Ended December 31 2021 2022 2021 2022 Fair Value Changes (1,356) (58) 7,392 (979)

------

![](q42022earningsslides-16m011.jpg)

11 2022 Revenue by Region (USD'000) Q4 2022 \| FY 2022 Q4 Jan - Dec Revenue by region Three-Month Ended December 31 2021 2022 YoY % APAC (Excluding China) 16,842 7,146 -58% China 41,314 52,143 26% EMEA 8,076 4,747 -41% USA 540 761 41% Total 66,772 64,797 -3% Revenue by region Twelve-Month Ended December 31 2021 2022 YoY % APAC (Excluding China) 38,190 52,566 38% China 93,326 132,469 42% EMEA 19,542 15,809 -19% USA 918 3,651 298% Total 151,976 204,495 35%

------

![](q42022earningsslides-16m012.jpg)

12 2022 Financial Highlights Q4 2022 \| fy 2022 $327.7M $128.7M Cash position $410.5M Order Backlog HpCO-53.5Ah Cell Expansion Capex Solid cash position – $327.7M cash (includes short-term investment) Expansion CAPEX of $128.7M, supporting ongoing 4GWh capacity expansions for HpCO-53.5Ah, Adds c. $1BN new revenue potential U.S. footprint is expanding; growing asset base, to support ESS and CV business, remains unlevered Record backlog of $410.5M – underpins high growth forecast, HpCO-53.5Ah cell rapid adoption across CV and ESS

------

![](q42022earningsslides-16m013.jpg)

OUTLOOK

------

![](q42022earningsslides-16m014.jpg)

14 2023 Outlook Q4 2022 \| fy 2022 On the path to achieve profitability within the next 2-3 years. ANNUAL REVENUE POTENTIAL backlog Strong Backlog & Technology Supports Multi-Year High Growth Phase 65%-75% revenue growth $410.5M supported by energy storage business in the U.S. and strong demand in Europe Clarksville, TN location benefits from IRA at $45/KWh on its domestic battery cell and module production. 2GWh=$90M IRA potential p.a. Anticipate significant uptick in orders and backlog supported by new commercial vehicle and energy storage projects Cell and module facility in Huzhou will begin deliveries in Q1 2GWh New U.S. cell and module facility in Clarksville, TN will be online in Q4 2GWh New backlog due to unmatched technical performance HpCO-53.5Ah cell accounts for >80% And a 10m sqm pilot line for polyaramid separator 4GWh = $1BN Exit 2023 New Capacity from 2022-2023

------